Last reviewed · How we verify

LT3 (liothyronine) — Competitive Intelligence Brief

LT3 (liothyronine) (LT3 (liothyronine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thyroid hormone replacement. Area: Endocrinology.

phase 3 Thyroid hormone replacement Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

LT3 (liothyronine) (LT3 (liothyronine)) — M. Medici. Liothyronine is a synthetic form of triiodothyronine (T3) that binds to thyroid hormone receptors to increase metabolic rate and cellular energy production.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LT3 (liothyronine) TARGET LT3 (liothyronine) M. Medici phase 3 Thyroid hormone replacement Thyroid hormone receptor alpha (TRα), Thyroid hormone receptor beta (TRβ)
Levothyroxine-Na + iodide Levothyroxine-Na + iodide Sanofi marketed Thyroid hormone replacement therapy Thyroid hormone receptors (TR-alpha and TR-beta)
Tirosint®-SOL Tirosint®-SOL IBSA Institut Biochimique SA marketed Thyroid hormone replacement Thyroid hormone receptors (TR-alpha and TR-beta)
L-T4+T3 (thyroid tablet) L-T4+T3 (thyroid tablet) Zhongshan Hospital Xiamen University marketed Thyroid hormone replacement therapy Thyroid hormone receptors (TR-alpha, TR-beta)
Levoxyl Levothyroxine Sodium Pfizer Inc. marketed Thyroid hormone replacement Thyroid receptor proteins attached to DNA
Cytomel Liothyronine Sodium Pfizer Inc. marketed Thyroid hormone replacement Thyroid receptor proteins attached to DNA
Euthyrox (levothyroxine) Euthyrox (levothyroxine) University Medical Center Groningen marketed Thyroid hormone replacement Thyroid hormone receptors (TR-alpha and TR-beta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thyroid hormone replacement class)

  1. Pfizer Inc. · 2 drugs in this class
  2. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  3. IBSA Institut Biochimique SA · 1 drug in this class
  4. M. Medici · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Meyer Children's Hospital IRCCS · 1 drug in this class
  7. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
  8. Oregon Health and Science University · 1 drug in this class
  9. Sanofi · 1 drug in this class
  10. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LT3 (liothyronine) — Competitive Intelligence Brief. https://druglandscape.com/ci/lt3-liothyronine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing